Noting that “biotechnology and healthcare penny stocks are making waves in the market”, the author of today’s article highlights four biotech penny stocks to watch that have been gaining attention this year, both for developments related to the COVID-19 crisis and developments unrelated to the COVID-19 crisis. For these four biotech penny stocks to watch, CLICK HERE.
“While large-cap stocks might spike slightly on certain headlines, more times than not, penny stocks tend to experience a compound effect,” notes the author of today’s article, who proceeds to examine three penny stocks that have recently had big news – and what that news could mean for those stocks heading into the final week of July. For more, CLICK…
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment…
Are we approaching the end of the TINA – “There Is No Alternative” (to buying stocks) – trade? The author of today’s article believes that’s likely the case, stating that “U.S. stocks are trading at a historically high premium… And in the coming weeks, stocks are about to get a lot more expensive. This, coupled with the realities associated with…
Given the fact that it has already demonstrated remarkable performance without even having any products with regulatory approval for sale, just where could biotech CRISPR Therapeutics, with its focus on the treatment of serious diseases using its proprietary CRISPR/Cas9 gene-editing platform, be five years from now? For more on the promise of this firm’s pipeline projects, CLICK HERE.
When it comes to making money on options, the author of today’s article observes that “being right on the direction of a stock is half the battle. You need to know which options to buy too to maximize your gains.” With this in mind, the author proceeds to outline a simple options trade that could result in a gain of…
After being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little…
While most of the attention in the biotech sector is focused on potential COVID-19 treatments or vaccines, the author of today’s article argues that there’s “a better way to play the sector, which is via companies whose roles in the daily grind of drug manufacturing and research will remain crucial regardless of the ups and downs of any particular acute…
With their shares having surged by more than 484%, 500% and 275%, respectively, the three stocks highlighted in today’s article are three of the best-performing pharmaceutical stocks over the past year – and despite them having already experienced monster moves higher, it may not be too late to get in on these stocks’ gains. For more on these three pharmaceutical…
The Fed may have helped the stock market rally from the March coronavirus collapse, but the author of today’s article warns that “a new and still largely overlooked risk has emerged with the calming of the COVID-19 crisis…And if this risk starts to manifest itself going forward, it will likely bring the U.S. stock market to its knees.” What is…